KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Deferred Tax (2023 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Long-Term Deferred Tax for 7 consecutive years, with $126.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Deferred Tax rose 7.8% year-over-year to $126.0 million, compared with a TTM value of $126.0 million through Dec 2025, up 7.8%, and an annual FY2025 reading of $126.0 million, up 7.8% over the prior year.
  • Long-Term Deferred Tax was $126.0 million for Q4 2025 at Alnylam Pharmaceuticals, up from $98.6 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $126.0 million in Q4 2025 and bottomed at $10.1 million in Q4 2023.
  • Average Long-Term Deferred Tax over 3 years is $93.8 million, with a median of $105.8 million recorded in 2025.
  • The sharpest move saw Long-Term Deferred Tax surged 1056.94% in 2024, then increased 7.8% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $10.1 million in 2023, then soared by 1056.94% to $116.9 million in 2024, then increased by 7.8% to $126.0 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for ALNY at $126.0 million in Q4 2025, $98.6 million in Q3 2025, and $104.4 million in Q2 2025.